Clinical trials: Blood Pressure, High
Pulmonary Arterial Hypertension
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose.
- Trial name
- VIP Extend (NCT03795428)
- Testing
- Pemziviptadil (PB1046) Injection
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Hypertension, Pulmonary
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH).
- Trial name
- HARMONIZE (NCT06814145)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Belgium and 10 more
- Volunteers
- 440 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension and Dyslipidemia
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-386 in healthy volunteers under fasting conditions.
- Trial name
- NCT05552495
- Testing
- CKD-386(4) F1, CKD-386(4) F2, D013, D326, D337
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Pulmonary
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor
BAY63-2521 Riociguat leads to the relaxation of smooth muscle cells in pulmonary arteria and may also inhibit abnormal remodeling of lung blood vessels.
- Trial name
- RESPITE (NCT02007629)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 61 people
- Sponsor
- Bayer
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a…
- Trial name
- NCT01342094
- Testing
- DE-111 ophthalmic solution, Timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Arterial Hypertension, Albuminuria
Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al.
- Trial name
- NCT02376075
- Testing
- Linagliptin
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- ikfe-CRO GmbH
Essential Hypertension
A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.
- Trial name
- NCT07700875
- Testing
- QR12000 Compound Tablets 75 mg, QR12000 Compound Tablets 150 mg, QR01019 potassium salt 50 mg
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
RV - Right Ventricular Abnormality, LV Dysfunction
Pediatric Ventricle Function Assessment Study
This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction.
- Conditions
- RV - Right Ventricular Abnormality, LV Dysfunction, Pulmonary Hypertension, TOF
- Trial name
- NCT06739057
- Where
- United States
- Volunteers
- 3,993 people, healthy volunteers welcome
- Sponsor
- HBI Solutions Inc.
Retina Disease, Glaucoma
P200TE Agreement and Precision Study
This study is a prospective comparative, randomized, single center study to assess agreement and precision of the P200TE in comparison to the predicate device in normal subjects, subjects with glaucoma, and subjects with retinal…
- Conditions
- Retina Disease, Glaucoma, Normal
- Trial name
- NCT05536401
- Testing
- P200TE, Predicate Device
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Essential Arterial Hypertension
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02521233
- Testing
- Candesartan + Chlorthalidone (8mg+12,5mg), Candesartan + Chlorthalidone (8 mg + 25 mg), losartan+hydrochlorothiazide
- Sponsor
- EMS
Medication Adherence, Glaucoma
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective.
- Trial name
- NCT03506568
- Testing
- Devers Drop Device (D3) app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universal Adherence LLC
Hypertension
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
- Trial name
- NCT01420068
- Testing
- SPP100
- Where
- 25 sites in United States, Guatemala and 5 more
- Volunteers
- 106 people
- Sponsor
- LXO Group
Glaucoma
A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients
The primary objective of the clinical study is to evaluate the efficacy and safety for Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.
- Trial name
- NCT00972426
- Testing
- carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Prehypertension, Hypertension, Stage I
A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure
The purpose of this study is to evaluate and compare the efficacy of B244 in treating patients with hypertension.
- Trial name
- NCT02998840
- Testing
- B244, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 132 people
- Sponsor
- AOBiome LLC
Open-Angle Glaucoma, Ocular Hypertension
To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension
To investigate the intraocular pressure (IOP)-lowering effect and safety of DE-104 ophthalmic solution in patients with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00656240
- Testing
- DE-104 ophthalmic solution, DE-104 vehicle
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Hypertension
Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)
The purpose of this study is to determine the efficacy of clevidipine injection versus placebo in treating preoperative hypertension.
- Trial name
- ESCAPE-1 (NCT00093249)
- Testing
- clevidipine
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- The Medicines Company
Hypertension
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with…
- Trial name
- NCT05769608
- Testing
- lorundrostat Dose 1, lorundrostat Dose 2
- Where
- 104 sites in United States
- Volunteers
- 285 people
- Sponsor
- Mineralys Therapeutics Inc.
Renal Impairment
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers
The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in renal impairment patients and healthy volunteers.
- Trial name
- NCT01148368
- Testing
- fimasartan
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Pulmonary
Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
Local, prospective, multicenter, non-comparative, non-interventional, observational study. It is planed to assess compliance of patients with PH (pulmonary hypertension) with the physician's recommendation in real practice.
- Trial name
- IVENT (NCT01971450)
- Testing
- Iloprost (Ventavis, BAYQ6256)
- Where
- Russia
- Volunteers
- 89 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
The aim of this study is to examine inhalation behavior in patients enrolled in the German Ventavis patient support program Ventaplus when these patients are switched from Ventavis (Iloprost) 10 μg/mL to Ventavis (Iloprost) 20…
- Trial name
- VENTASWITCH (NCT02826252)
- Testing
- Iloprost,(Ventavis, BAYQ6256), I-Neb AAD system
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.